Interestingly, PIK3CA/AKT pathway inhibitors robustly killed resistant tumors in the presence of OT and yet had only moderate impact on tumor cell killing in the parental, therapy-sensitive cells (Fig. 3C and Supplementary Data 5). Here, PIK3CA is linked to neoplasm.